ABSTRACT Introduction: Nivolumab is the first checkpoint inhibitor approved for the treatment of nonsquamous NSCLC. We report results from the nivolumab Italian expanded access program focusing on never-smokers and patients with EGFR-mutant nonsqamous NSCLC.
Introduction
Nonsquamous NSCLC comprises almost 50% of all advanced cases of NSCLC. 1, 2 For patients with advanced nonsquamous NSCLC, there are few therapeutic options and the prognosis remains poor. 1, 2 For many years, docetaxel has been the most commonly used treatment after failure of platinum-based chemotherapy despite its poor tolerability and limited activity. 3 In this therapeutic setting, LUME-Lung 1 was the first phase III trial to demonstrated a survival advantage with the addition of the antiangiogenic agent nintedanib to docetaxel. 4 Similar findings were reported with ramucirumab, a monoclonal antibody targeting the vascular endothelial growth factor receptor 2. 5 However, in both studies the toxicity due to combination therapies was higher than that due to docetaxel monotherapy.
Nivolumab was the first fully human programmed death 1 (PD-1) immune checkpoint inhibitor (ICI) antibody approved for the second-line treatment of patients with advanced NSCLC. In phase III studies (CheckMate 017 and Checkmate 057), nivolumab demonstrated a significant overall survival (OS) benefit versus that with docetaxel in pretreated patients with advanced squamous NSCLC (objective response rate (ORR) 20% versus 9% [p ¼ 0.008] and median OS 9.2 versus 6.0 months [p < 0.001]) and nonsquamous NSCLC (ORR 19% versus 12% [p ¼ 0.02] and median OS 12.2 versus 9.4 months [p ¼ 0.002]). 6, 7 To date, no validated predictive biomarkers to select patients to receive nivolumab have been found; however, recent and developing data suggest a potential role of expression of human programmed death ligand 1 (PD-L1) combined with tumor mutation burden. [8] [9] [10] Despite encouraging results, the activity of nivolumab and other ICIs has appeared to be more limited in never-smokers and in patients whose tumors harbor activating EGFR mutations, 6, 7, [11] [12] [13] [14] [15] [16] [17] [18] [19] although there have been overlaps in smokers and patients with EGFR mutations. 7, 20 The Italian expanded access program (EAP) in advanced nonsquamous NSCLC provided an opportunity for patients to gain access to nivolumab before it became commercially available in Italy. In contrast to the eligibility criteria in controlled clinical trials, the main eligibility criteria for the EAP were very broad, allowing the investigators to describe the use of nivolumab in a setting comparable with clinical practice (Appendix). Here we report preliminary results from the Italian nivolumab EAP, with a focus on never-smokers and patients with EGFRmutant tumors. The overall analysis of the EAP data is ongoing and will be presented in another publication. To our knowledge, this is the first specific examination of data on nivolumab in never-smokers and patients with advanced nonsquamous NSCLC with EGFR-mutant tumors.
Methods

Patients
The study eligibility criteria for patients were as follows: a histologically or cytologically confirmed diagnosis of stage IIIB or IV nonsquamous NSCLC; age 18 years or older; life expectancy of at least 6 weeks; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 or lower; and adequate hematologic, hepatic, and renal function. Patients were required to have progression or recurrence during or after at least one systemic chemotherapy for advanced or metastatic nonsquamous NSCLC (patients not eligible for platinum-based chemotherapy were allowed to receive alternative cytotoxic regimens). Each line of therapy had to be preceded by disease progression. Switching drugs on account of toxicity did not define a new treatment line. Patients who received definitive chemoradiation therapy for locally advanced disease or platinum-containing neoadjuvant or adjuvant chemotherapy and presented with disease progression or relapse no more than 6 months after conclusion of therapy were eligible. Patients must have concluded prior chemotherapy, palliative radiotherapy, tyrosine kinase inhibitor (TKI) therapy, or immunotherapy (a vaccine, growth factor, or cytokine) at least 2 weeks before administration of nivolumab, with stabilization or resolution of all adverse events (AEs) to baseline levels. Patients with central nervous system metastases were eligible if the metastases were treated and there was neurological return to baseline levels for at least 14 days before administration of nivolumab. In addition, patients had to have stopped taking corticosteroids or be taking a stable or decreasing dose of no more than 10 mg of prednisone daily (or the equivalent).
Exclusion criteria included symptomatic interstitial lung disease, carcinomatous meningitis, and any prior therapy with anti-PD-1, anti-PD-L1, anti-programmed death ligand 2, anti-CT137, or anti-cytotoxic Tlymphocyte-associated protein 4 antibody or any other drugs targeting checkpoint pathways or T-cell costimulation. Patients were also excluded if they were eligible for another trial with nivolumab or if they had human immunodeficiency virus infection or known autoimmune disease, with the exception of residual hypothyroidism due to an autoimmune condition, type 1 diabetes mellitus, or psoriasis not requiring systemic treatment.
Study Design and Treatment
Nivolumab was provided upon physician request. The EAP guidelines were approved at each participating center, and physicians had to comply with generally accepted good clinical practice and ethical standards. All patients had to provide written informed consent. Nivolumab, 3 mg/kg, was administered intravenously every 2 weeks until disease progression, unacceptable toxicity, or consented withdrawal before 24 months. Dose reductions were not allowed; however, nivolumab administration could be delayed in the event of toxicity. Treatment could be continued beyond an initial progression if in the physician's opinion, the patient experienced clinical benefit. This was allowed only in the absence of rapid disease progression, if the ECOG PS was stable, and if the drug was well tolerated.
Assessments
There were no prespecified end points; physicians were encouraged to carefully document disease progression. The requested efficacy data included investigator-assessed ORR, survival, and progression information. Radiological tumor assessment was performed every 8 to 12 weeks by a total body computed tomography scan (brain, chest, and abdomen) or chest and abdominal computed tomography scan and brain magnetic resonance imaging according to the clinical practice of each oncological center. Patient safety was evaluated on the basis of physical examination, ECOG PS, hematologic test results, thyroid function, and chemistry tests per local regulations and standards of care. AEs were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0; study investigators assessed the relationship of AEs to nivolumab therapy. Each patient's smoking habit was recorded by an investigator using behavioral anamnesis. We defined never-smokers as patients who had smoked fewer than 100 cigarettes in their life, former smokers as patients had who stopped smoking at least 12 months before their cancer diagnosis, and current smokers as active smokers or patients who had stopped smoking less than 1 year before diagnosis of their cancer. Every single institution used local standard methods (generally, Sanger sequencing, pyrosequencing, or next-generation sequencing) to detect EGFR mutations in exons 18, 19, 20, and 21 . The choice of testing methods was primarily based on the available cytological or histological sample.
Statistical Analysis
Patients in both the safety and efficacy analyses received at least one dose of nivolumab. EGFR status was determined according to local procedures. ORR, disease control rate (DCR) (i.e., the rates of complete response, partial response, and stable disease combined), progression-free survival (PFS), and OS were evaluated. PFS and OS were estimated by using the Kaplan-Meier method; median times were reported with 95% confidence intervals. PFS was calculated from the start of nivolumab treatment until any evidence of progressive disease or death, whichever occurred first. OS was calculated from the start of nivolumab treatment until death from any cause or last follow-up. A proportional hazards regression model was used to test the association of each factor with survival time, and a stepwise selection procedure was implemented to identify the independent prognostic roles of patient characteristics. Hazard ratios and their 95% confidence intervals were reported. Statistical analyses were computed with IBM SPSS Statistics 21.0 statistical software (IBM Corporation, Armonk, NY).
Results
Patients and Treatment
Between May 2015 and April 2016, 1588 patients with a diagnosis of nonsquamous NSCLC were enrolled in 153 Italian centers; 305 patients (19.2%) were never-smokers and 102 patients (6.4%) had a tumor harboring an EGFR mutation. In never-smokers, EGFR status was available for 287 patients; 51 never-smokers (16.7%) had a tumor harboring an activating EGFR mutation (Supplementary Table 1 ). Baseline characteristics are shown in Table 1 and Supplementary  Table 2 . Among never-smokers and patients with EGFR-mutant tumors, respectively, 44.9% and 43.1% were male, the median age was 65 years in both groups (range 29-87 and 40-83), 33.4% and 27.5% were older than 70 years, and 93.8% and 93.1% had an ECOG PS 0 or 1.
With a median follow-up of 7.7 months (range 0.1-21.9), never-smokers and patients with EGFR-mutant tumors received a median of six doses (range and eight doses (range 1-46) of nivolumab, respectively. In all, 263 never-smokers and 91 patients with EGFR-mutant tumors discontinued nivolumab treatment: 76.4% and 72.5% because of disease progression and 8.7% and 12.1% because of death, respectively. A total of 89 never-smokers (29.2%) and 36 patients with EGFR mutation (35.3%) received at least one postnivolumab therapy. Ten never-smokers (3.3%) and 13 patients with EGFR mutation (12.7%) were treated with osimertinib after nivolumab treatment (Table 2) .
Efficacy
Responses, PFS, and OS data are shown in Table 3 . Among patients with EGFR-mutant and wild-type tumors, respectively, the ORR was 8.8% versus 19.6% (p ¼ 0.007), the DCR was 30.4% versus 45.8% (p ¼ 0.003), the median PFS was 3.0 versus 3.0 months (p ¼ 0.004), the 12-month PFS rate was 14.0% versus 21.9%, the median OS was 8.3 versus 11.0 months (p ¼ 0.46) ( Fig. 1A) , and the 12-month OS rate was 48.2% versus 47.5%. Complete responses were reported only for patients with EGFR wild-type tumors (0.5%).
Among patients with EGFR-mutant tumors who were never-smokers or former and current smokers, respectively, the median OS was 5.6 versus 14.1 months (p ¼ 0.12) (Fig. 1B) . Among never-smokers and smokers, respectively, the ORR was 9.2% versus 21.5% (p ¼ 0.0001), the DCR was 42.0% versus 47.1% (p ¼ 0.11), the 12-month PFS rate was 12.5% versus 24.5%, the median OS was 10.0 versus 11.6 months (p ¼ 0.11), and the 12-month OS rate was 44.2% versus 49.3%. Among never-smokers with EGFR-mutant or wild-type tumors, respectively, the ORR was 1.9% versus 11.0% (p ¼ 0.04), the DCR was 21.6% versus 44.9% (p ¼ 0.002), the median PFS was 2.0 versus 3.0 months (p ¼ 0.001), the 12-month PFS rate was 4.9% versus 13.2%, the median OS was 5.6 versus 11.0 months (p ¼ 0.14) (Fig. 2A) (Fig. 2B) , and the 12-month OS rate was 55.6% versus 48.3%. In a multivariate analysis, ECOG PS (2 versus 0-1) and the presence of metastases (brain, liver, and/or bone) were independent prognostic factors for OS and PFS in never-smokers (Supplementary Table 3 ). In patients with EGFR-mutant tumors, only metastatic sites (liver and bone) seemed to affect OS (Supplementary Table 4 ).
Safety
Any-grade treatment-related AEs occurred in 33% of the overall EAP population, 31% of never-smokers, and 36% of patients with EGFR-mutant tumors (Table 4) . Grade 3 or 4 treatment-related AEs occurred in 6% of the overall EAP population, 6% of never-smokers, and 7% of patients with EGFR-mutant tumors. Discontinuation due to treatment-related AEs occurred in 2.9% of never-smokers, 2.9% of patients with EGFR-mutant Figure 1 . Overall survival according to EGFR status in the overall population (A) and according to smoking status in the EGFR mutant population (B). OS, overall survival; CI, confidence interval; HR, hazard ratio. tumors, and 2.6% of the overall EAP population. Among never-smokers, treatment-related AEs leading to discontinuation were mainly related to hepatic and gastrointestinal toxicities; in patients with EGFR-mutant tumors, they were mainly related to hypotension and gastrointestinal events. All immune-related AEs were managed by using prespecified protocol management algorithms.
Discussion
In the Italian cohort of the nivolumab EAP, smoking and the presence of EGFR mutations seem to affect shortterm (ORR and DCR) but not medium-(PFS) or longterm (OS) outcomes. The prevalence of never-smokers and patients with EGFR-mutant tumors was consistent with that reported in previously published studies. 7, [11] [12] [13] [14] ORR was significantly higher in patients with wild-type EGFR than in patients with EGFR mutation and in former and current smokers than in never-smokers. Although there were no statistically significant differences in median OS between subgroups, a positive trend in OS benefit seems to exist in patients with EGFR wildtype versus in patients with EGFR-mutant tumors and in former and current smokers versus in never-smokers, which is similar to the results reported in a phase III study with nivolumab (Checkmate 057) 7 and studies of other ICIs with NSCLC. 11, 13, 14 The absence of statistically significant differences in OS between the groups might be attributed to poststudy treatment (see Table 2 ). When matching smoking habits and EGFR mutational status, we found median OS times of 11.0 versus 5.6 months and 14.1 versus 11.3 months in never-smokers with EGFR wild-type versus in the subgroups with EGFRmutant tumors and in former and current smokers with EGFR-mutant versus EGFR wild-type tumors subgroups, respectively. These differences were all not statistically significant, but they could suggest a potentially different benefit between EGFR-mutant and wild-type tumors in never-smokers versus in former and current smokers that is likely due to a different tumor mutational burden or PD-L1 expression.
To our knowledge, this is the first report to examine subgroups according to both smoking habits and EGFR mutational status. Previous published reports demonstrated benefit for subgroups selected according to PD-L1 expression, either in tumor cells or in tumorinfiltrating immune cells. 11, 14 Preclinical work demonstrated that EGFR-driving mutations in lung tumors inhibit immunity by activating the PD-1/PD-L1 pathway and suppressing T-cell activity. Mutant EGFR functions are possibly associated with other oncogenes determining immune escape. 21 In addition, different lung (11) 3 (1) 10 (10) 2 (2) 193 (12) 14 (1 (15) 4 (1) 14 (14) 2 (2) 194 (12) 28 (2) Dyspnea 20 (7) 3 (1) 3 (3) 1 (1) 79 (5) 19 (2) Pneumonitis 9 (3) 1 (<1) 2 (2) 1 (1) 31 (2) 9 (<1) AE, adverse event.
tumor genotypes correlate with PD-L1 expression according to tumor protein p53 gene (TP53), and serine/ threonine kinase 11 gene (STK11) mutational status, or smoking habits. 22 Different acquired mutations, such as T790M (as a resistance mechanism to EGFR TKIs), may affect nivolumab treatment and PD-L1 expression. 23 A meta-analysis showed less benefit in terms of PFS in smokers when treated with an EGFR TKI. 24 Safety results were similar between never-smokers, patients with EGFR-mutant tumors, and the overall population, and they were comparable to those from the nivolumab arm of CheckMate 057 7 and others reported in the literature. 7, [11] [12] [13] [14] [15] [16] [17] 19 Nivolumab was generally well tolerated in all subgroups. Grade 3 to 4 treatmentrelated AEs were few and generally manageable with specific treatments algorithms. Only 2.9% of neversmokers and patients with EGFR-mutant tumors, respectively, discontinued therapy on account of treatment-related AEs.
This Italian EAP report has some limitations, including the small number of never-smokers and patients with EGFR mutations, the higher rate of brain metastases in the EGFR-mutant subgroups, the observational design, the lack of detailed EGFR mutational analysis and evaluation of tumor PD-L1 expression, and imbalances in baseline patient characteristics and use of previous therapies. The limited benefit trend demonstrated with nivolumab in never-smokers and patients with EGFR-mutant tumors confirmed similar results from other trials. 7, 11, 13, 14 However, controversial data are emerging regarding the efficacy of immunotherapy in never-smokers and patients with EGFR-mutant tumors. The phase III OAK trial suggested an OS benefit, even for patients who are never-smoker, 12 and the phase II ATLANTIC study 15 provides evidence of a benefit in patients with EGFR mutations and high PD-L1 levels.
Clearly, our results are exploratory and the statistical power to compare the subgroups of smokers and neversmokers with EGFR mutations could be questionable. Nevertheless, these preliminary data could suggest that matching smoking habits with EGFR mutational status may be of value in predicting outcomes with nivolumab. It is likely that EGFR-driving mutations or the tumor mutational burden in former and current smokers may explain the benefit provided by nivolumab in certain subgroups with nonsquamous NSCLC. 8 Although further investigation is needed, our results could suggest that certain subgroups with nonsquamous NSCLC (e.g., never-smokers with EGFR wild-type tumors and perhaps smokers with EGFR-mutant tumors) could benefit from nivolumab.
